Viridian Therapeutics stock
VRDNNASDAQViridian Therapeutics, Inc., HealthcareISIN US92790C1045
47Score 47 out of 100, Weak
Price and trend
77 / 100
Price history
+5.3% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 41% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 86).
The price is 9.8% below its 52-week high. Largest decline in 12 years: 100% (June 2014 to March 2020).
Chart figures for advanced users
- SMA 50$22.59
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$21.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)86
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.30
- The lowest closing price of the last twelve months.
- Resistance$33.78
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Viridian Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.46B, is number 95 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $70.85M (up 23,359.9% year on year) and a loss of $342.6M.
- For fiscal 2026, analysts expect on average revenue of $75.13M (up 6%) and adjusted earnings per share of −$3.55.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 440 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 132.2% a year since 2020, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $955.21M, financial debt $243.27M.Stability 51
Weaknesses
- DilutionShare count up 164% since 2022.Capital allocation 18
- Loss-makingLoss of $453.58M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$343.44M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Jun 2026, revenue rose 279% on the same quarter a year earlier. Revenue has grown strongly since 2012, at around 24% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −513%, net −484%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 4 Nov 2026EPS reported −$0.81 (expected −$1.02)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 18.8% since 15 Oct 2026.
- Earnings per share
- −$3.55+9.6%
- Revenue
- $75.13M+207.9%
- Earnings per share
- −$2.09+18.8%
- Revenue
- $314.19M+34.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $245,000 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Tousignant JenniferSale
19 Aug 2026, Chief Legal Officer
- Shares
- 10,000
- Price
- $24.50
- Value
- $245,000
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Viridian Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Denali TherapeuticsDNLI $3.72B37
- Viking TherapeuticsVKTX $3.63B34
- Legend BiotechLEGN $3.61B37
- Arcutis BiotherapeuticsARQT $3.59B62
- CelcuityCELC $3.55B28
- Dyne TherapeuticsDYN $3.37B36
- Disc MedicineIRON $3.34B42
- Telix PharmaceuticalsTLX $3.23B40
ETFs that hold Viridian Therapeutics
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.30% | 0.40% | €1.49B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.11% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.05% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.